| Inotersen treatment for patients with hereditary transthyretin amyloidosis MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ... New England Journal of Medicine 379 (1), 22-31, 2018 | 1605 | 2018 |
| Correction of a pathogenic gene mutation in human embryos H Ma, N Marti-Gutierrez, SW Park, J Wu, Y Lee, K Suzuki, A Koski, D Ji, ... Nature 548 (7668), 413-419, 2017 | 1347 | 2017 |
| Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy CY Ho, ME Mealiffe, RG Bach, M Bhattacharya, L Choudhury, ... Journal of the American College of Cardiology 75 (21), 2649-2660, 2020 | 384 | 2020 |
| Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial SB Heitner, D Jacoby, SJ Lester, A Owens, A Wang, D Zhang, J Lambing, ... Annals of internal medicine 170 (11), 741-748, 2019 | 346 | 2019 |
| Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy DP Judge, SB Heitner, RH Falk, MS Maurer, SJ Shah, RM Witteles, ... Journal of the American College of Cardiology 74 (3), 285-295, 2019 | 286 | 2019 |
| Aficamten for symptomatic obstructive hypertrophic cardiomyopathy MS Maron, A Masri, ME Nassif, R Barriales-Villa, M Arad, N Cardim, ... New England Journal of Medicine 390 (20), 1849-1861, 2024 | 243 | 2024 |
| Hypertrophic cardiomyopathy: the future of treatment CV Tuohy, S Kaul, HK Song, B Nazer, SB Heitner European journal of heart failure 22 (2), 228-240, 2020 | 228 | 2020 |
| Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy MS Maron, A Masri, L Choudhury, I Olivotto, S Saberi, A Wang, ... Journal of the American College of Cardiology 81 (1), 34-45, 2023 | 215 | 2023 |
| Automated echocardiographic detection of severe coronary artery disease using artificial intelligence R Upton, A Mumith, A Beqiri, A Parker, W Hawkes, S Gao, M Porumb, ... Cardiovascular Imaging 15 (5), 715-727, 2022 | 139 | 2022 |
| Triheptanoin versus trioctanoin for long‐chain fatty acid oxidation disorders: a double blinded, randomized controlled trial MB Gillingham, SB Heitner, J Martin, S Rose, A Goldstein, ... Journal of Inherited Metabolic Disease: Official Journal of the Society for …, 2017 | 127 | 2017 |
| Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial GM Felker, SD Solomon, B Claggett, R Diaz, JJV McMurray, M Metra, ... JAMA cardiology 7 (1), 26-34, 2022 | 114 | 2022 |
| Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF JR Teerlink, R Diaz, GM Felker, JJV McMurray, M Metra, SD Solomon, ... Journal of the American College of Cardiology 78 (2), 97-108, 2021 | 112 | 2021 |
| Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy CY Ho, I Olivotto, D Jacoby, SJ Lester, M Roe, A Wang, CB Waldman, ... Circulation: Heart Failure 13 (6), e006853, 2020 | 97 | 2020 |
| Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial TH Brannagan, AK Wang, T Coelho, M Waddington Cruz, MJ Polydefkis, ... European Journal of Neurology 27 (8), 1374-1381, 2020 | 70 | 2020 |
| Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial GD Lewis, AA Voors, A Cohen-Solal, M Metra, DJ Whellan, JA Ezekowitz, ... Jama 328 (3), 259-269, 2022 | 68 | 2022 |
| Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial PJ Dyck, JC Kincaid, PJB Dyck, V Chaudhry, NA Goyal, C Alves, H Salhi, ... Muscle & nerve 56 (5), 901-911, 2017 | 63 | 2017 |
| Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis MA Gertz, M Scheinberg, M Waddington-Cruz, SB Heitner, C Karam, ... Expert review of clinical pharmacology 12 (8), 701-711, 2019 | 49 | 2019 |
| Ma et al. reply H Ma, N Marti-Gutierrez, SW Park, J Wu, T Hayama, H Darby, ... Nature 560 (7717), E10-E23, 2018 | 48 | 2018 |
| Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4 A Masri, MV Sherrid, TP Abraham, L Choudhury, P Garcia-Pavia, ... Journal of Cardiac Failure 30 (11), 1439-1448, 2024 | 47 | 2024 |
| Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design CJ Coats, MS Maron, TP Abraham, I Olivotto, MMY Lee, M Arad, N Cardim, ... Heart Failure 12 (1), 199-215, 2024 | 46 | 2024 |
Daniel JacobyYale School of MedicineVerified email at yale.edu
